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Abstract [currently 246]:  
 
Objective: To estimate the national cost of ADEs resulting from inappropriate medication-
related alert overrides in the U.S. inpatient setting. 
Materials and Methods: We used three different regression models (Basic, Model 1, Model 2) 
with model inputs taken from the medical literature. A random sample of 40,990 adult inpatients 
at the Brigham and Women’s Hospital (BWH) in Boston with a total of 1,639,294 medication 
orders was taken. We extrapolated BWH medication orders using 2014 National Inpatient 
Sample (NIS) data. 
Results: Using three regression models, we estimated that 29.7 million adult inpatient discharges 
in 2014 resulted in between 1.02 billion and 1.07 billion medication orders, which in turn 
generated between 75.1 million and 78.8 million medication alerts, respectively. Taking the basic 
model (78.8 million), we estimated that 5.5 million medication–related alerts might have been 
inappropriately overridden, resulting in approximately 196,600 ADEs nationally. This was 
projected to cost between $871 million and $1.8 billion for treating preventable ADEs. We also 
estimated that clinicians and pharmacists would have jointly spent 175,000 hours responding to 
78.8 million alerts with an opportunity cost of $16.9 million.   
Discussion and Conclusion: These data suggest that further optimization of hospitals 
computerized provider order entry systems and their associated clinical decision support is 
needed and would result in substantial savings. We have erred on the side of caution in 
developing this range, taking two conservative cost estimates for a preventable ADE that did not 
include malpractice and litigation costs, or costs of injuries to patients.  
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Background and Significance 
Adverse drug events (ADEs) result in more than 770,000 injuries or deaths in U.S. 
hospitals each year.(1-3) These specific injuries result from medical interventions related to a 
drug. In addition to the human impact, which is great, ADEs that occur during hospitalisation are 
also costly for hospitals to treat, with expenses estimated to be between $1.56 and $5.6 billion 
annually.(4-6) The individual cost of a significant or life-threatening ADE has been estimated to 
range between $2,852 and $8,116 in community hospitals.(7) These costs are likely to be 
conservative estimates as they did not include malpractice and litigation costs, or the costs of 
injuries to patients. 
Many of these ADEs are preventable and the number could be reduced if hospitals made 
changes to their systems for drug ordering and administration.(4) Computerized provider order 
entry (CPOE) with clinical decision support (CDS) has the potential to improve the drug 
ordering process by guiding health care providers with their prescribing. These systems can alert 
providers to potential hazardous drug-drug interactions (DDIs),(8, 9) or prompt them to adjust 
the drug dose based on a patient’s renal function.(10, 11) Computerized systems can also detect 
ADEs early, even if they are not preventable, so that appropriate action can be taken to lessen the 
severity of the event. 
However, the success of these computerized systems depends on how well they have 
been designed and used. Too many alerts may lead to ‘alert fatigue’ for the user, which can result 
in providers overlooking even important medication-related alerts.(12) Much of our recent work 
has focused on evaluating the appropriateness of providers’ alert overrides;(8, 9, 13, 14) few data 
are available to quantify the additional resource utilization associated with inappropriately 
overriding these alerts. In this study, we estimated the national cost of preventable ADEs 
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resulting from inappropriate alert overrides in the US inpatient setting. 
 
Materials and Methods 
We used the following approach to estimate the national cost of preventable ADEs:  
 Step 1: Estimate the number of national inpatient medication orders. This involved 
drawing a random sample of patient data from the Brigham and Women’s Hospital 
(BWH), Boston, Massachusetts, U.S., and the national inpatient sample (NIS).  
 Step 2: Calculate the number of inappropriate alert overrides and avoidable ADEs. This 
involved drawing on estimates from the published medical literature.(4, 14, 15)   
 Step 3: Estimate the national cost of ADEs resulting from inappropriate medication-
related alert overrides. Two values were taken from the medical literature.(5, 7)  
We next describe each of these steps in turn, providing further details about how our estimates 
were calculated.  
 
Step 1: Estimate the number of national inpatient medication orders 
We estimated the number of national inpatient medication orders by multiplying the 
average number of orders per inpatient in our BWH sample by the number of discharges from 
the NIS in 2014. The NIS is part of the Healthcare Cost and Utilization Project, sponsored by the 
Agency for Healthcare Research and Quality (AHRQ), and is the largest all-payer inpatient care 
database in the U.S. It contains clinical and resource use information on all individuals covered 
by Medicare, Medicaid, private insurance, or uninsured. 
We recognized that patient characteristics may have differed between both samples and 
time periods, and wanted to ensure consistency. We obtained a sample of BWH inpatient data 
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from July 1, 2015 to June 30, 2016, and used this single year of data to estimate the relationship 
between patient characteristics (age, gender, length of stay [LOS], and acuity) and BWH 
inpatient medication orders. We used Medicare Severity-Diagnosis Related Group (MS-DRGs) 
and All Patient Refined DRGs (APR-DRGs) weights in the regression as a proxy for patient 
acuity. APR-DRGs can be thought of as a refinement of MS-DRGs (finer gradations of 
conditions by disease and severity) to include all payers and all patients. We obtained data on 
age, gender, LOS from the NIS ‘Inpatient Core File’ in our analysis, applying weights as 
necessary. We obtained MS-DRGs from the ‘Inpatient Core File’ and APR-DRGs from the 
‘Disease Severity Measures File’ from the NIS. DRG weights were also updated annually, with 
the elimination of old DRGs and the creation of new DRGs in NIS data (as old treatments are 
discontinued, and new treatments emerge), and we accounted for this in our economic analysis. 
We used the entire BWH sample to develop the regression model and then extrapolated 
the results to the most recent year of NIS data available (2014). As the patient characteristics of 
our BWH sample differed from the national population (e.g., gender, age, LOS, and DRG 
weight, with further details presented in our results section below), we used three different 
regression models (Basic, Model 1, Model 2) to extrapolate BWH mediation orders to NIS data. 
For the basic model, we firstly ran a regression on the BWH sample to estimate the importance 
of each of these factors (the coefficients for gender, age, LOS, and DRG weight) on the number 
of medication orders the patient had, and then secondly ran the NIS data through the regression 
equation (i.e., each observation with the patient’s age, gender, LOS and DRG weight) to predict 
the number of medication orders we would expect for each patient after adjusting for these 
sample characteristics. However, regressions like this with limited data are not an exact science, 
and the interaction between the four variables and the number of medication orders might not be 
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purely linear, so we also produced variations of the basic model to see how that affected 
predicted medication orders e.g., Model 1, we included an interaction between age and gender; 
Model 2, we included an interaction between age and gender and we also included age squared. 
The results presented below are similar for all three.  
Appendix 1, which is available on request, contains details on how we cleaned, merged, 
and adjusted BWH and NIS data. For the primary results, we have chosen to present our 
estimates using the Basic model and MS DRG extrapolation. 
 
Step 2: Calculate the number of inappropriate alert overrides and avoidable ADEs.  
We drew on the published medical literature to estimate the number of drug-allergy, 
drug-drug, duplicate drug, and renal-dosing alerts triggered, and inappropriately overridden.(14, 
15) A drug allergy interaction alert was displayed if the patient has a definite (the drug being 
ordered was an exact match to the allergen), probable (the drug being ordered was in the same 
allergen group) or possible reaction (cross-sensitivity was considered likely), as well as 
the specific type of reaction that the patient may be at risk of developing, for example, hives. A 
drug-drug interaction alert was generated if an undesirable interaction was likely to occur 
between two drugs and cause serious injury to the patient. A duplicate drug alert was displayed if 
there were two or more orders for the same medication or for medications in the same 
therapeutic class. The renal-based medication substitution alerts were based on a calculation of 
the patient’s creatinine clearance using weight, height, age, sex, and most recent creatinine level, 
and suggested substituting a particular medication. All alerts were interruptive and required the 
user to give a reason if he or she decided to override the alert. We also calculated the number of 
avoidable ADEs resulting from inappropriate overrides in U.S. hospitals nationally.(4) 
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Step 3: Estimate the national cost of ADEs resulting from inappropriate medication-related 
alert overrides 
We used two estimates for the cost of a preventable ADE in the inpatient setting from the 
published medical literature. The first value was taken from a study conducted in two tertiary 
care centers by Bates et al., which found an average avoidable ADE cost of $4,685 in 1993.(5) 
The second estimate was taken from a study conducted in six community hospitals by Hug et al., 
which found that a preventable ADE cost $3,511 in 2005/2006.(7) We inflated both reported 
costs per ADE to 2016 dollars ($8,968 and $4,430, respectively) using the Producer Price Index 
for primary services at general medical and surgical hospitals.(16) 
 
Estimating the time and cost of responding to CDS alerts 
We also estimated the time that a clinician and pharmacist can spend viewing and 
responding to each medication-related alert (approximately 4 seconds), and the implicit hourly 
wage ($90 and $58, respectively) to determine the opportunity cost of that time.(16, 17) We also 
calculated a loaded hourly rate ($117 and $76, respectively) to include cover for additional 
charges (e.g., insurance, sick time, vacation time), and payroll taxes.   
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Results 
Step 1: Estimate the number of national inpatient medication orders 
The full BWH inpatient sample contained 40,990 patients. Using three regression models 
to extrapolate BWH medication orders (1,639,294) to NIS data, we estimated that 29.7 million 
adult inpatient discharges in 2014 resulted in 1.02 billion to 1.07 billion medication orders (see 
Table 1). These extrapolations also showed how there was only 4.25 percent difference between 
assigning APR-DRGs compared to MS-DRGs to all patients. Within each extrapolation, there 
was less than a 0.5 percent difference between the smallest (e.g., Model 2_Column 1) and the 
largest estimate (e.g., Basic Model_Column 1). 
 
Table 1. Number of estimated national inpatient medication orders in 2014 by DRG type 
Regression Model 
Specification 
2014 NIS data using 
MS-DRG Weights 
2014 NIS data using 
APR-DRG Weights 
Total 
(billions) 
per Patient* 
Total 
(billions) 
per Patient* 
Basic Model 1.073 36.1 1.028 34.6 
Model 1 1.070 36.0 1.024 34.4 
Model 2 1.069 35.9 1.023 34.4 
* calculated from BWH sample 
 
 
Comparison of BWH data sample and NIS 
We compared the characteristics of the BWH inpatient sample to the NIS sample (Table 
2). Compared to the NIS sample, the BWH inpatient sample was more female (61 percent versus 
59 percent), younger (average age 55.2 versus 57.3), more severely ill (as measured by a longer 
hospital LOS; 5.2 days versus 4.7 days), and with a higher average MS-DRG weight (2.21 versus 
1.49) and higher average APR-DRG weight (1.54 versus 1.14).  
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We found MS-DRGs and APR-DRGs were reported for about 43 and 56 percent of the 
BWH inpatient sample, respectively. We compared the characteristics of the full BWH inpatient 
sample to the subset of the BWH sample that had MS-DRGs only. The two BWH samples (full 
sample and subsample) of patients were similar to NIS patients in terms of age and gender, but 
were both more severely ill than the national average measured by LOS and DRG weight. As the 
BWH is a large, urban, teaching, tertiary care hospital, it was reasonable to expect that the full 
BWH inpatient sample would be more severely ill than the national average.  
The full BWH inpatient sample also included 158 (0.004%) patients for whom TRIS-
DRGs were reported. TRIS-DRGs are for TriCare patients, which is the healthcare provider for 
members of the U.S. military, and their DRG weights were found to be very similar (but not 
identical) to MS-DRGs.  
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Table 2. A comparison of BWH and NIS patient samples 
  
Variable 
BWH Sample (1st July 15 – 30th Jun 16) 
2014 NIS [a] 
Full Sample [a] 
Sample patients 
with MS-DRGs 
[a] 
Sample patients 
with APR-DRGs 
[a] 
Mean SD Mean SD Mean SD Mean SD 
Female (%) 61 49 52 50 68 47 59 49 
Age 55.16 18.90 68.51 15.01 44.75 14.58 57.26 20.48 
LOS [b] 5.22 6.74 5.87 6.69 4.72 6.74 4.74 6.26 
MS-DRG 
Weight [b, c] 
1.84 2.18 
2.21 2.19     1.49 1.38 
APR-DRG 
Weight [b, c] 
    1.54 2.12 1.14 1.32 
Med. Orders 
per patient 
39.99 44.69 44.93 46.12 36.12 43.16 NA NA 
Total number 
of patients in 
each sample 
[b] 
40,990 [d] 17,954 22,878 5,949,232 [e] 
[a] Excluding patients under the age of 18. 
[b] Please refer to Appendix 1 for details on how the data was cleaned and adjusted. 
[c] For full BWH inpatient sample, DRG weights are a weighted average of patients with MS 
DRGs and patients with APR DRGs; for NIS sample, DRG weights are the average if all patients 
are assigned MS DRGs or all patients are assigned APR DRGs, respectively. 
[d] The full BWH inpatient sample included about 158 BWH patients (0.004%) for whom TRIS-
DRGs were reported, thus the number of MS DRG patients and APR DRG patients do not sum to 
the total sample size. 
[e] 5.9 million observations in the NIS represented 29.7 million hospital patient discharges.   
 
 
 
Step 2: Calculate the number of inappropriate alert overrides and avoidable ADEs. 
 
Starting with the projected number of inpatient medication orders (1.02 billion to 1.07 
billion) estimated in the previous step, we multiplied this by the percent (7.3) of medication 
orders that had triggered alerts in the BWH sample. We concentrated on only four main types of 
medication-related alerts: drug-allergy, drug-drug, duplicate drug, and renal-dosing, using rates 
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from the medical literature.(14, 15) This resulted in an estimated 75.1 million to 78.8 million 
medication alerts in U.S. hospitals in 2014, depending on which model and set of DRG weights 
were used. Taking the basic model with MS-DRG weights (78.8 million), we then used this to 
estimate the total number of alert overrides (57.6 million). Of these, we estimated that 5.5 
million might have been inappropriate overridden, resulting in approximately 196,600 ADEs 
(see Table 3). Using all three regression models and both types of DRG extrapolations, the 
projected national number of ADEs ranged from 196,600 (Basic model & MS-DRG weights) to 
187,400 (Model 2 and APR-DRG weights).  
 
Table 3. Estimated number of national alerts and overrides by alert type, appropriate and 
inappropriate overrides, and ADEs using basic model and MS-DRG weights for NIS.  
Alert Type 
No. of 
Alerts 
(millions) 
No. of 
Overrides 
(millions) 
(%)[a] 
Appropriate 
Overrides 
(millions) 
(%)[b] 
Inappropriate 
Overrides 
(millions) 
(%)[c] 
Inappropriate 
overrides 
resulting in 
ADEs 
(thousands) 
(%)[d] 
Drug allergy 48.23 39.51 (81) 38.12 (96.5) 1.38 (3.5) 13.8 (1.0) 
Drug–drug 
interaction 
13.77 9.39 (68.2) 5.82 (62.0) 3.57 (38.0) 107.0 (3.0) 
Duplicate drug 16.15 8.38 (51.9) 8.21 (98.0) 0.17 (2.0) 1.7 (1.0) 
Renal-dosing[e] 0.61 0.39 (62.4) 0.008 (2.2) 0.37 (97.8) 74.0 (20.0) 
Total  78.75 
57.65 
(73.3) 
52.16  
(90.5) 
5.49 
(9.5) 
196.6 
(3.6) 
[a] The number of alert overrides (column 3) was calculated by multiplying the number of alerts e.g., 
48.23 for drug allergy (column 2) by the percentage of alerts overridden e.g., 81% for drug allergy. 
[b] The number of appropriate overrides (column 4) was calculated by multiplying the number of 
overrides e.g., 39.51 million for drug allergy (column 3) by the percentage of appropriate overrides e.g., 
96.5% for drug allergy 
[c] The number of inappropriate overrides for drug allergy (column 5) was calculated by multiplying the 
number of overrides e.g., 39.51 million for drug allergy (column 3) by the percent of overrides deemed 
inappropriate e.g., 3.5% for drug allergy (column 5) taken from Slight et al.(14). Percentages for the other 
alert types were taken from Nanji et al.(15)  
[d] Since 1.0% of inappropriate drug allergy overrides resulted in ADEs, we ended up with 13.8 thousand 
ADEs. 
[e] To calculate the % of renal-dosing alert overrides, we drew on the results of Chertow et al’s study 
where clinicians overrode 9,012 (62.4%) of the 14,440 alerts generated. If the clinician’s final order fell 
within the CDS parameters, we deemed this as ‘appropriate’. 
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Step 3: Estimate the national cost of ADEs resulting from inappropriate medication-related 
alert overrides 
We multiplied the estimated 196,600 ADEs expected to occur in U.S. hospitals because 
of inappropriate alert overrides by the estimated cost per preventable ADE based on Bates et 
al.(5) This was projected to result in costs of $1,762.6 million for treating preventable ADEs. 
Using the estimated cost of a preventable ADE published by Hug et al, this was projected to 
result in costs of $871 million for treatment.  
 
Table 4. Estimated time and total cost of both viewing and responding to alerts, and of 
preventable ADEs resulting from inappropriate alert overrides by alert type 
 Estimated Time Responding to 
Alerts by Alert Type, Basic 
Model and MS-DRG Weights 
for NIS 
Total Cost of ADEs by Alert 
Type, Basic Model and MS DRG 
Weights for 2014 NIS (millions of 
2016 $$) 
Alert Type 
Hours 
responding to 
alerts 
(thousands) 
Opportunity 
cost of 
responding to 
alerts (millions 
2016 $$) 
Annual cost of 
ADEs, 
Bates, et al.(5) 
(millions) 
Annual cost of 
ADEs,  
Hug, et al.(7) 
(millions) 
Patient 
allergy 107.2 
$10.3 $124.0 $61.3 
Drug–drug 
interaction 30.6 
$2.9 $959.6 $474.0 
Duplicate 
drug 35.9 
$3.5 $15.0 $7.4 
Renal-dosing 1.3 $0.13 $664.0 $328.0 
Total 175.0 $16.9 $1,762.6 $871 
 
 
Estimating the time and cost of responding to CDS alerts 
The 78.8 million alerts were projected to cost 87,500 hours of clinician time and 87,500 
hours of pharmacist time over the course of a year, with an opportunity cost of $10.2 million and 
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$6.6 million, respectively. The avoided costs associated with the averted ADEs exceeded the 
opportunity cost of clinicians’ and pharmacists’ time responding to the alerts by more than two 
orders of magnitude using the Bates et al’s cost per ADE,(5) and by more than 1.5 orders of 
magnitude using the Hug et al’s cost per ADE.(7) Thus, the intervention would ‘break even’ even 
if clinicians and pharmacists each took almost seven minutes per alert using the Bates cost per 
ADE, and almost seven minutes per alert using the Hug cost per ADE. 
For the basic regression model (see Table 5), we estimated that if clinicians and 
pharmacists each spent an average of 4 seconds to respond to each alert and the average implicit 
wage for clinicians and pharmacists is $117 and $76 per hour, respectively, then clinicians and 
pharmacists would have jointly spent 175,000 hours (87,500 hours each) responding to the 78.8 
million alerts (MS-DRG extrapolation) compared to 167,600 hours (83,800 hours each) 
responding to the 75.5 million alerts (APR-DRG extrapolation). This would result in an 
opportunity cost of $16.9 million (MS-DRG extrapolation) compared to $16.2 million (APR-
DRG extrapolation). Using our cost estimates of an ADE and extrapolating using MS-DRG 
weights, 5.5 million inappropriate alert overrides resulted in 196,600 ADEs costing the 
healthcare system $1,760 million based on Bates et al., and $871 million based on Hug et al. 
Extrapolating using APR-DRG weights, 5.26 million inappropriate alert overrides resulted in 
188,300 ADEs, costing the healthcare system $1,690 million based on Bates et al., and $834 
million based on Hug et al study. (see Table 5). 
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Table 5. The estimated cost of ADEs and time responding to alerts 
Estimated time responding to alerts by model specification and DRG type 
Regression 
Model 
Specification 
NIS MS-DRG Weights NIS APR-DRG Weights 
Hours 
Responding to 
Alerts 
(thousands) 
Opportunity 
Cost 
Responding 
to Alerts 
(millions  
2016 $$) 
Hours 
Responding to 
Alerts 
(thousands) 
Opportunity 
Cost 
Responding to 
Alerts (millions  
2016 $$) 
Basic Model 175.0 $16.9 167.7 $16.2 
Model 1 174.4 $16.8 167.0 $16.1 
Model 2 174.3 $16.8 166.9 $16.1 
Estimated Cost of ADEs by Model and DRG Type (millions of 2016 $$) 
Regression 
Model 
Specification 
NIS MS-DRG Weights NIS APR-DRG Weights 
Cost of ADEs Cost of ADEs 
Bates, et al. Hug, et al. Bates, et al. Hug, et al. 
Basic Model $1,762.6 $871 $1,688.8 $834.3 
Model 1 $1,756.9 $868 $1,682.4 $831.1 
Model 2 $1,755.1 $867 $1,680.8 $830.3 
 
 
 
Discussion 
We estimated that 29.7 million adult inpatient discharges in 2014 resulted in 
approximately a billion medication orders, which in turn generated about 75 million medication 
alerts in 2014. We then estimated that approximately 5.5 million medication–related alerts were 
inappropriately overridden, resulting in approximately 196,600 ADEs nationally, costing 
between $871 million and $1,763 million. These data suggest that further optimization of 
hospitals computerized provider order entry (CPOE) systems and their associated clinical 
decision support is needed and would result in substantial savings.    
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This model-based economic analysis has focused primarily on setting out a range of 
plausible estimates for the total cost of ADEs resulting from inappropriate medication-related 
alert overrides in the US inpatient setting. We have erred on the side of caution in developing 
this range, taking into account two cost estimates for a preventable ADE from the published 
medical literature. One cost estimate was taken from a study conducted at the same large tertiary 
care hospital from which we drew our two inpatient samples (full sample and subsample).(5) 
However, this BWH cost estimate ($4,685) could be considered an overestimation, as our data 
showed how this hospital treated patients who were more severely ill compared to the national 
average. That said, our second cost estimate ($3,511) was taken from a study conducted in six 
community hospitals by Hug et al., where the costs of a preventable ADE appeared slightly 
lower.(7) These costs are also likely to be conservative estimates as they did not include 
malpractice and litigation costs, or the costs of injuries to patients. As the majority of health care 
expenses (diagnoses and intervention) are usually incurred early in patient’s hospital stay, Taheri 
et al. only estimated the incremental cost of the final hospital day for a patient.(18) This value 
can reasonably be assumed to be an underestimate of the true costs in most cases, as ADEs are 
likely to result in an increased LOS of between 2.2 days and 3.1 days.(5, 7)  
Our economic analysis focused only the consequences for hospitals of providers 
inappropriately overriding medication-related alerts. We considered the more common types of 
medication-related alerts likely to have been implemented in hospitals in this analysis (drug-
allergy, drug-drug, duplicate drug, renal suggestion). One question which emerges is where 
should hospitals focus their efforts to help reduce these preventable costs in the future? We 
know from the published literature that the rate of inappropriate alert overrides varies 
substantially by alert type.(8) Drug-drug interaction alerts in particular were found to be often 
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inappropriately overridden by healthcare providers. A key issue here is that too many drug-drug 
warnings are overridden because providers are bombarded with these alerts, and a key approach 
will be to display only the most important warnings. The most common override reason cited for 
drug-drug interactions was ‘will monitor as recommended’.(7, 8) Drug monitoring is another 
task that is often not carried out as intended,(9) with some providers possibly less clear about 
what specific parameters should be monitored or indeed when such monitoring should be 
performed. Hospital CPOE systems with CDS could be further optimized to address this by 
including more specific information in the content of their alerts or facilitating the ordering of a 
particular drug level at the same time as these alerts are presented. Although it had some of the 
highest values, adjustment of drug dosing according to level of renal function and age is also not 
yet done in most institutions,(19) which represents another major missed opportunity. We 
acknowledge that our results could be interpreted in many different ways; for example, 
institutions could interpret the low opportunity cost of the alert to the high cost of avoiding an 
ADE and be encouraged to add more medication-related alerts. However, our analysis was 
conducted at one point in time and does not observe the rates of change over time. If the numbers 
of medication-related alerts were to increase, alert fatigue amongst system users may also 
increase. We anticipate that this ‘diminishing returns’ to additional alerts could actually increase 
the cost in terms of frequency of ADEs per order, and so we would advise caution in interpreting 
our results in this way.  
 
Limitations 
The evidence base from which we obtained our model inputs has limitations. Firstly, our 
two cost estimates were obtained from studies conducted in the state of Massachusetts, and it is 
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possible that these costs may not be generalizable to other states due to differences in patient 
populations. Secondly, our analysis is also dependent upon the quality and accuracy of the 
hospitals’ cost accounting systems from which we obtained our cost estimates for a preventable 
ADE. Thirdly, as mentioned above, we obtained data on age, gender, LOS from the NIS 
‘Inpatient Core File’ in our analysis, applying weights as necessary. We noted that a very small 
amount of patient observations (n = 3,507) out of a total of 5,952,739 patient observations were 
missing at least one of these variables and so the number of medication orders was predicted for 
5,949,232 patient observations representing 29.7 million hospital discharges. Fourthly, we 
considered the more common types of medication-related alerts in this analysis (drug-allergy, 
drug-drug, duplicate drug, renal suggestion), but acknowledge that there are other types of 
medication-related alerts, such as age-based and formulary alerts, which have not been included. 
Furthermore, our inappropriate alert override rates were obtained from studies conducted at a 
large, academic healthcare center.  
 
Conclusion 
The cost of ADEs resulting from inappropriate medication-related alert overrides is 
substantial. We estimated a projected total cost of $871 million for U.S. hospitals to treat these 
preventable ADEs; this cost did not include the costs of injuries to patients or malpractice costs, 
which can be considerable from a societal perspective. There is scope to further optimize 
hospitals CPOE systems with CDS to improve patient safety; additional resource invested in this 
area is warranted.    
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